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The landscape of healthcare is constantly changing, with new and innovative treatment 
techniques regularly emerging. We are also improving the ability to investigate (and prevent) 
specific inherited conditions through pre-implantation diagnosis and other medical 
interventions. One such category of medical intervention is mitochondrial donation, which is 
currently permitted (under strict conditions) in the United Kingdom but is prohibited in 
Australia. Recently, under the directions of the Hon Greg Hunt, MP (Minister for Health) the 
National Health and Medical Research Council (NHMRC) opened a dialogue to consider the 
regulatory, scientific and ethical issues of mitochondrial donation.  
 
What is Mitochondrial Donation 
 
Before addressing the ethical and regulatory issues around mitochondrial donation it is 
important to provide a brief overview of what the process involves. The following, very 
simple, explanation is dran from the NHMRC’s Issues Paper, released as a part of the 
consultation process. Mitochondrial donation is a new assisted reproductive technology to 
help people avoid transmitting mitochondrial DNA disease to their biological children. 
‘Mitochondria are DNA-containing structures found in human cells. Although small, 
mitochondria are vital for normal cell biology and health and they provide energy for cells, 
and support many other important functions’ (Issues Paper, p7). At its simplest, 
‘mitochondrial donation allows for an embryo to be produced using the nuclear DNA from a 
man and a woman, and the mitochondrial DNA from an egg donated by another woman. 
There are a number of techniques for mitochondrial donation. The aim is to replace mutant 
mitochondrial DNA, and avoid transmission of mitochondrial DNA disease.mitochondrial 
donation involves’ (Issues Paper, p14). It is the combining of DNA from three individuals that 
gives rise to the  complex legal and ethical issues surrounding mitochondrial donation.  
 
The Global Story 
 
Globally there is a lack of consistency with regards to the regulation of mitochondrial 
monation. Indeed, there is even a lack of consistency around the nomenclature of the 
process. It is variously referred to as mitochondrial donation, mitochondrial transfer, 
mitochondrial replacement therapy. We have chosen to adopt the language of the NHMRC 
Review and therefore refer to it as mitochondrial donation. At the moment, the UK is the only 
country to have passed specific, targeted laws relating to mitochondrial donation.  
 
In 2014, the Food and Drug Administration (FDA) in the USA requested the Institute of 
Medicine of the National Academies of Sciences, Engineering and Health to explore the 
broader implications of mitochondrial donation (although they referred to it as mitochondrial 
transfer). The Report (Mitochondrial Replacement Techniques, Ethical, Social and Policy 
Considerations(USA Report)) was released in early 2016 and referred to its ‘foundational 
question’ as being ‘whether it is ethically permissile for clinical investigations of MRT to 
proceed’ (USA Report, overview).  
 
The conclusion of the USA Report was that mitochondrial donation was ethically permissible 
so long as there was compliance with governing ‘conditions and principles’ (USA Report, 
overview). A significant limitation was that it should only proceed with male embryos. The 
rationale for this limitation was that, because the mitochondria from a male are not passed 
on to subsequent generations, and therefore the heritability of the mitochondrial transfer 
would be limited to female offspring. However, shortly after this report was released any 
further investigation was prohibited via ‘congressional funding restrictions on heritable 
genetic modification’ (Pompei, 2019, 385). There relevant law is the US Act s749  Consolidated 
Appropriations Act 2016 and it has been ratified every year since 2016, the FDA cannot 
approve or fund any further research which acts  an effective prohibition on MRT in the 
United States.  
 
The position in the UK is quite different and has come about after a lengthy consultation and 
review process. Taking place over a 12 year period, this included a number of public 
consultations and the commission of three scientific reviews. In 2015, the Human Fertilisation 
and Embryology (Mitochondrial Donation) Regulations were passed and the UK became the 
first country to specifically address mitochondrial donation in law. It is a careful and 
comprehensive regulatory instrument that defines specific terms, amends the Human 
Fertilisation and Embryology Act 1990 and establishes a regime where clinics and participants 
must be licensed. So far, one clinic in Newcastle has been licensed and a number of treatment 
licenses have been granted. It is unknown if, or how many, children have been born. 
 
The position in other countries is varied. Last year the Singaporean Bioethics Advisory 
Committee released a consultation paper which signalled a public consultation and broader 
enquiry. However it appears that this has not progressed and there is no indication that, 
despite headlines such as ‘Singapore could become the second country to legalize 
mitochondrial replacement therapy’, a change of law is imminent. In 2018 Ishil and Hibino 
undertook a study of 16 countries and summarised the regulatory landscape in the following 
terms: ‘Not regulated:Northern Cyprus and Ukraine; insufficiently regulated: Albania, India, 
Israel, Italy, Mexico and Taiwan; pronuclear transfer prohibited but other MMT regulated 
insufficiently: Canada, Czech Republic, Japan and Spain; allogeneic MMT not allowed but 
autologous MMT regulated insufficiently: Turkey and the United Arab Emirates; and MMT 
largely prohibited: China and the USA’ (Ishil and Hibino, 2018, 106). 
 
The short version of the global story is therefore that it is complicated. 
 
The Australian Story 
 
Before considering the Australian position it is necessary to introduce the National Health and 
Medical Research Council (NHMRC). It is an independent statutory agency operating under 
the National Health and Medical Research Council Act 1992 (Cth). The NHMRC is, under the 
guidance of the CEO, tasked with inquiring into, issuing guidelinesand advising the community 
on matters relating to: 
 
                              (i)  the improvement of health; and 
                             (ii)  the prevention, diagnosis and treatment of disease; and 
                            (iii)  the provision of health care; and 
                            (iv)  public health research and medical research; and 
                             (v)  ethical issues relating to health; and 
 
In addition there is responsibility to provide advice to the Commonwealth, the States and the 
Territories on these matters and to directly advise the Minister for Health  (NHMRC Act, s7). It was 
in this capacity that on 23 September 2019 the NHMRC opened a public consultation on the 
possible introduction of mitochondrial donation into Australian clinical practice.  
 
In 2018, the Australian Senate Community Affairs References Committee undertook an 
inquiry into the science of mitochondrial donation and related matters. The Report from the 
inquiry made a number of recommendations. In response, the Australian government asked 
the CEO of the NHMRC to facilitate public consultation and seek expert advice on relevant 
legal, regulatory, scientific and ethical issues. To facilitate meaningful public consultation, the 
NHMRC has released an Issues Paper addressing legal, ethical and social considerations 
around mitochondrial donation, and it was from this paper that the explanation of 
mitochondrial donation provided above was drawn. To further assist in the process, a 
Mitochondrial Donation Expert Working Committee (MDEWC) was established by the NHMRC 
CEO to provide her with expertise and perspectives on relevant issues, including assisting with 
the writing of the issues paper and conduct of the community consultation.  
 
The regulation of artificial reproductive technology (ART) in Australia is complex because of 
its status as a federation of six states, two territories and the separate federal 
Commonwealth. When it comes to ART, what we have is a pot pourri of different legal and 
non-legal regimes. The state of Victoria was the first place globally to enact specific ART 
legislation, in the form of the Infertility (Medical Procedures) Act 1984. This Act imposed a 
strict system of regulation based on criminal penalties. Victorian law has undergone 
significant transformation over time, to respond to new technological advances, to provide 
more comprehensive guidance and to reflect changing community attitudes. The early 
Victorian lead was followed by South Australia and Western Australia, and, much later, New 
South Wales. The Northern Territory requires clinics to comply with South Australian 
legislation. Each of the regulatory regimes is different although all recognise the paramount 
concern for the welfare of the child born as a consequence of the provision of ART.   
 
This is not to say that the conduct of ART elsewhere in Australia is unregulated. The NHMRC 
has provided a set of helpful ethical guidelines on the use of ART in clinical practice and 
research. Accreditation of ART clinics by the Fertility Society of Australia and the Reproductive 
Technology Accreditation Council is dependent on compliance with the Council’s Code of 
Conduct, which in turn requires compliance with these NHMRC guidelines. The guidelines 
have been updated to reflect technological advances and changes in community attitudes on 
a number of occasions, most recently in 2017. The introduction of techniques such as 
mitochondrial donation adds another layer of complexity to this regulatory regime as it 
introduces the possibility of intervention for more than mere reproductive purposes. The 
focus is on disease prevention (and perhaps eradication) and will result in the destruction of 
some embryos and the alteration of others.  
 
From the time when IVF became a practical reality, the cloning of human beings, hitherto the 
realm of science fiction, started to become more tangible. The birth of Dolly the sheep in 1996 
heightened concerns about this new reality, and prompted an outpouring of ethical debate 
and calls for legislative action. The ART-specific laws in Victoria, South Australia and Western 
Australia each already included provisions prohibiting human cloning. However, the definition 
of cloning in each statute was different and the regulatory regime associated with this 
technology across the nation was messy and ambiguous. In parallel with developments in 
cloning technology, embryonic stem cell technology was advancing at as rapid a pace. This 
technology, though not uncontroversial because of concerns it raised about the destruction 
of human embryos, was recognised as offering significant therapeutic benefits. 
 
The governments of Australia responded rapidly to the call for legislative responses to the 
ethical and social concerns associated with human cloning and embryonic stem cell research. 
By 2002, the Research involving Human Embryos Act and the Prohibition of Human Cloning 
Act had been passed by federal parliament. The states and territories agreed to enact mirror 
legislation to ensure national uniformity. Both of these Acts placed specific and clear 
limitations on what could, and could not, be done with human embryos. Legislating to 
prohibit human cloning was uncontroversial, and the Act was passed with minimal debate. 
However, legislating to allow some uses of human embryos for research was more 
contentious. In an unusual move, members of parliament were given a ‘free vote’ to allow 
them to vote with their conscience rather than along party lines. The Research involving 
Human Embryos Act, though eventually passed, was subjected to one of the longest debates 
in the history of the Australian parliament. By 2005, members of parliament had sufficient 
comfort with the ways in which the technology was developing to allow the creation of 
embryos using cloning technology for research, but only under very limited, strictly regulated 
circumstances. The Prohibition of Human Cloning Act thus became the Prohibition of Human 
Cloning for Reproduction Act. 
 
The Research involving Human Embryos Act allows certain embryos to be used for research 
and training, subject to strict licence conditions issued by the ERLC. The Prohibition of Human 
Cloning for Reproduction Act, in contrast, sets out that certain activities are prohibited. It is a 
criminal offence to undertake prohibited activities, with a penalty of up to 15 years 
imprisonment. Under these laws, some laboratory-based research into mitochondrial 
donation may be permissible in Australia under licence. However, mitochondrial donation for 
clinical purposes is currently prohibited. If mitochondrial donation is to proceed into clinical 
practice in Australia, the law will need to be amended. Public consultation is a vital step in 
assessing whether it is appropriate to do so.  
 
The Australian story is therefore only just beginning and there is yet to be any formal 
presentation of recommendations or conclusion from the consultation process. The opening 
of the discussion however represent a modest first step and reflects a careful approach to 
possible reform.  
 
Authors’ note: We write in our capacities as law academics and as chairs of two NHMRC 
committees, the Mitochondrial Donation Expert Working Committee (MDEWC) and the 
Embryo Research Licensing Committee (ERLC). This discussion seeks to neither endorse nor 
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